

Claims

1. A pharmaceutical paclitaxel composition comprising:
paclitaxel;
polyethoxylated castor oil; and
an acid; said composition being such that at least 96.6% of the paclitaxel potency is retained
when the composition is stored at 40°C for seven days.
2. The pharmaceutical paclitaxel composition of claim 1, further comprising ethanol.
3. The pharmaceutical paclitaxel composition of claim 1, wherein said acid is an organic acid.
4. The pharmaceutical paclitaxel composition of claim 1, wherein said acid is a mineral acid.
5. The pharmaceutical paclitaxel composition of claim 3, wherein said acid is citric acid.
6. The pharmaceutical paclitaxel composition of claim 5, wherein said citric acid is
monohydrous.
7. The pharmaceutical paclitaxel composition of claim 5, wherein the citric acid is hydrous.
8. The pharmaceutical paclitaxel composition of claim 5, wherein the citric acid is anhydrous.
9. The pharmaceutical paclitaxel composition of claim 3, wherein said acid is acetic acid.
10. The pharmaceutical paclitaxel composition of claim 2, wherein said acid is an organic
acid.

11. The pharmaceutical paclitaxel composition of claim 2, wherein said acid is a mineral acid.
12. The pharmaceutical paclitaxel composition of claim 10, wherein said acid is citric acid.
13. The pharmaceutical paclitaxel composition of claim 12, wherein said citric acid is monohydrous.
14. The pharmaceutical paclitaxel composition of claim 12, wherein the citric acid is hydrous.
15. The pharmaceutical paclitaxel composition of claim 12, wherein the citric acid is anhydrous.
16. The pharmaceutical paclitaxel composition of claim 10, wherein said acid is acetic acid.
17. An article of manufacture comprising a sealed container and a pharmaceutical paclitaxel composition disposed within said sealed container, said pharmaceutical paclitaxel composition comprising:
- paclitaxel;
 - a pharmaceutically-acceptable carrier; and
 - an acid; said composition being such that at least 96.6% of the paclitaxel potency is retained when said composition is stored at 40°C for seven days.
18. The article of manufacture of claim 17, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.
19. The article of manufacture of claim 18, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

20. The article of manufacture of claim 17, wherein said acid is an organic acid.
21. The article of manufacture of claim 17, wherein said acid is a mineral acid.
22. The article of manufacture of claim 20, wherein said acid is acetic acid.
23. The article of manufacture of claim 20, wherein said acid is citric acid.
24. The article of manufacture of claim 23, wherein said citric acid is anhydrous.
25. The article of manufacture of claim 23, wherein said citric acid is monohydrous.
26. The article of manufacture of claim 23, wherein said citric acid is hydrous.
27. The article of manufacture of claim 18, wherein said acid is an organic acid.
28. The article of manufacture of claim 18, wherein said acid is a mineral acid.
29. The article of manufacture of claim 27, wherein said acid is acetic acid.
30. The article of manufacture of claim 27, wherein said acid is citric acid.
31. The article of manufacture of claim 30, wherein said citric acid is anhydrous.
32. The article of manufacture of claim 30, wherein said citric acid is monohydrous.
33. The article of manufacture of claim 30, wherein said citric acid is hydrous.

FOIA b 7 - DEXTER

34. The article of manufacture of claim 19, wherein said acid is an organic acid.
35. The article of manufacture of claim 19, wherein said acid is a mineral acid.
36. The article of manufacture of claim 34, wherein said acid is acetic acid.
37. The article of manufacture of claim 34, wherein said acid is citric acid.
38. The article of manufacture of claim 37, wherein said citric acid is anhydrous.
39. The article of manufacture of claim 37, wherein said citric acid is monohydrous.
40. The article of manufacture of claim 37, wherein said citric acid is hydrous.
41. An article of manufacture produced by the process of:
- (a) obtaining a sealable container;
 - (b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that at least 96.6% of the paclitaxel potency is retained when the formulation is stored at 40°C for seven days;
 - (c) placing said pharmaceutical formulation in said sealable container;
 - (d) sealing said sealable container; and
 - (e) storing said pharmaceutical formulation in said sealed container for at least seven days.
42. The article of manufacture of claim 41, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

43. The article of manufacture of claim 42, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

44. The article of manufacture of claim 41, wherein said acid is an organic acid.

45. The article of manufacture of claim 41, wherein said acid is a mineral acid.

46. The article of manufacture of claim 44, wherein said acid is acetic acid.

47. The article of manufacture of claim 44, wherein said acid is citric acid.

48. The article of manufacture of claim 47, wherein said citric acid is anhydrous.

49. The article of manufacture of claim 47, wherein said citric acid is monohydrous.

50. The article of manufacture of claim 47, wherein said citric acid is hydrous.

51. The article of manufacture of claim 42, wherein said acid is an organic acid.

52. The article of manufacture of claim 42, wherein said acid is a mineral acid.

53. The article of manufacture of claim 51, wherein said acid is acetic acid.

54. The article of manufacture of claim 51, wherein said acid is citric acid.

55. The article of manufacture of claim 54, wherein said citric acid is anhydrous.

56. The article of manufacture of claim 54, wherein said citric acid is monohydrous.

101001-3330260

57. The article of manufacture of claim 54, wherein said citric acid is hydrous.
58. The article of manufacture of claim 43, wherein said acid is an organic acid.
59. The article of manufacture of claim 43, wherein said acid is a mineral acid.
60. The article of manufacture of claim 58, wherein said acid is acetic acid.
61. The article of manufacture of claim 58, wherein said acid is citric acid.
62. The article of manufacture of claim 61, wherein said citric acid is anhydrous.
63. The article of manufacture of claim 61, wherein said citric acid is monohydrous.
64. The article of manufacture of claim 61, wherein said citric acid is hydrous.
65. A pharmaceutical paclitaxel composition which is at least seven days old, comprising:
paclitaxel;
a pharmaceutically-acceptable carrier; and
an acid; said at least seven-day old composition being such that at least 96.6% of the original paclitaxel potency is retained when said composition is stored at 40°C for seven days, and said at least seven-day old composition having at least 96.6% of its original paclitaxel potency.
66. The pharmaceutical paclitaxel composition of claim 65, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.
67. The pharmaceutical paclitaxel composition of claim 66, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

68. The pharmaceutical paclitaxel composition of claim 65, wherein said acid is an organic acid.

69. The pharmaceutical paclitaxel composition of claim 65, wherein said acid is a mineral acid.

70. The pharmaceutical paclitaxel composition of claim 68, wherein said acid is acetic acid.

71. The pharmaceutical paclitaxel composition of claim 68, wherein said acid is citric acid.

72. The pharmaceutical paclitaxel composition of claim 71, wherein said citric acid is anhydrous.

73. The pharmaceutical paclitaxel composition of claim 71, wherein said citric acid is monohydrous.

74. The pharmaceutical paclitaxel composition of claim 71, wherein said citric acid is hydrous.

75. The pharmaceutical paclitaxel composition of claim 66, wherein said acid is an organic acid.

76. The pharmaceutical paclitaxel composition of claim 66, wherein said acid is a mineral acid.

77. The pharmaceutical paclitaxel composition of claim 75, wherein said acid is acetic acid.

78. The pharmaceutical paclitaxel composition of claim 75, wherein said acid is citric acid.

79. The pharmaceutical paclitaxel composition of claim 78, wherein said citric acid is anhydrous.

80. The pharmaceutical paclitaxel composition of claim 78, wherein said citric acid is monohydrous.

81. The pharmaceutical paclitaxel composition of claim 78, wherein said citric acid is hydrous.

82. The pharmaceutical paclitaxel composition of claim 67, wherein said acid is an organic acid.

83. The pharmaceutical paclitaxel composition of claim 67, wherein said acid is a mineral acid.

84. The pharmaceutical paclitaxel composition of claim 82, wherein said acid is acetic acid.

85. The pharmaceutical paclitaxel composition of claim 82, wherein said acid is citric acid.

86. The pharmaceutical paclitaxel composition of claim 85, wherein said citric acid is anhydrous.

87. The pharmaceutical paclitaxel composition of claim 85, wherein said citric acid is monohydrous.

88. The pharmaceutical paclitaxel composition of claim 85, wherein said citric acid is hydrous.

89. A pharmaceutical paclitaxel composition which is at least seven days old, comprising:
paclitaxel;

a pharmaceutically-acceptable carrier; and

an acid; said at least seven-day old composition being such that the composition comprises no more than 2.3% total impurities when said composition is stored at 40°C for seven days, and wherein said composition comprises no more than 2.3% total impurities.

90. The pharmaceutical paclitaxel composition of claim 89, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

91. The pharmaceutical paclitaxel composition of claim 90, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

92. The pharmaceutical paclitaxel composition of claim 89, wherein said acid is an organic acid.

93. The pharmaceutical paclitaxel composition of claim 89, wherein said acid is a mineral acid.

94. The pharmaceutical paclitaxel composition of claim 92, wherein said acid is acetic acid.

95. The pharmaceutical paclitaxel composition of claim 92, wherein said acid is citric acid.

96. The pharmaceutical paclitaxel composition of claim 95, wherein said citric acid is anhydrous.

97. The pharmaceutical paclitaxel composition of claim 95, wherein said citric acid is monohydrous.

98. The pharmaceutical paclitaxel composition of claim 95, wherein said citric acid is hydrous.

99. The pharmaceutical paclitaxel composition of claim 90, wherein said acid is an organic acid.

100. The pharmaceutical paclitaxel composition of claim 90, wherein said acid is a mineral acid.

101. The pharmaceutical paclitaxel composition of claim 99, wherein said acid is acetic acid.

102. The pharmaceutical paclitaxel composition of claim 99, wherein said acid is citric acid.

103. The pharmaceutical paclitaxel composition of claim 102, wherein said citric acid is anhydrous.

104. The pharmaceutical paclitaxel composition of claim 102, wherein said citric acid is monohydrous.

105. The pharmaceutical paclitaxel composition of claim 102, wherein said citric acid is hydrous.

106. The pharmaceutical paclitaxel composition of claim 91, wherein said acid is an organic acid.

107. The pharmaceutical paclitaxel composition of claim 91, wherein said acid is a mineral acid.

108. The pharmaceutical paclitaxel composition of claim 106, wherein said acid is acetic acid.
109. The pharmaceutical paclitaxel composition of claim 106, wherein said acid is citric acid.
110. The pharmaceutical paclitaxel composition of claim 109, wherein said citric acid is anhydrous.
111. The pharmaceutical paclitaxel composition of claim 109, wherein said citric acid is monohydrous.
112. The pharmaceutical paclitaxel composition of claim 109, wherein said citric acid is hydrous.
113. An article of manufacture which is at least seven days old, comprising a sealed container and a pharmaceutical paclitaxel composition disposed within said sealed container, said composition comprising:
- paclitaxel;
 - a pharmaceutically-acceptable carrier; and
 - an acid; said at least seven-day old composition being such that at least 96.6% of the original paclitaxel potency is retained when said composition is stored at 40°C for seven days, and said at least seven-day old composition having at least 96.6% of its original paclitaxel potency.
114. An article of manufacture according to claim 113, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.
115. An article of manufacture according to claim 114, wherein said pharmaceutically-acceptable carrier further comprises ethanol.
116. The article of manufacture of claim 113, wherein said acid is an organic acid.

117. The article of manufacture of claim 113, wherein said acid is a mineral acid.
118. The article of manufacture of claim 116, wherein said acid is acetic acid.
119. The article of manufacture of claim 116, wherein said acid is citric acid.
120. The article of manufacture of claim 119, wherein said citric acid is anhydrous.
121. The article of manufacture of claim 119, wherein said citric acid is monohydrous.
122. The article of manufacture of claim 119, wherein said citric acid is hydrous.
123. The article of manufacture of claim 114, wherein said acid is an organic acid.
124. The article of manufacture of claim 114, wherein said acid is a mineral acid.
125. The article of manufacture of claim 123, wherein said acid is acetic acid.
126. The article of manufacture of claim 123, wherein said acid is citric acid.
127. The article of manufacture of claim 126, wherein said citric acid is anhydrous.
128. The article of manufacture of claim 126, wherein said citric acid is monohydrous.
129. The article of manufacture of claim 126, wherein said citric acid is hydrous.
130. The article of manufacture of claim 115, wherein said acid is an organic acid.

TEDEXT "030304660

141. The article of manufacture of claim 137, wherein said acid is a mineral acid.
142. The article of manufacture of claim 140, wherein said acid is acetic acid.
143. The article of manufacture of claim 140, wherein said acid is citric acid.
144. The article of manufacture of claim 143, wherein said citric acid is anhydrous.
145. The article of manufacture of claim 143, wherein said citric acid is monohydrous.
146. The article of manufacture of claim 143, wherein said citric acid is hydrous.
147. The article of manufacture of claim 138, wherein said acid is an organic acid.
148. The article of manufacture of claim 138, wherein said acid is a mineral acid.
149. The article of manufacture of claim 147, wherein said acid is acetic acid.
150. The article of manufacture of claim 147, wherein said acid is citric acid.
151. The article of manufacture of claim 150, wherein said citric acid is anhydrous.
152. The article of manufacture of claim 150, wherein said citric acid is monohydrous.
153. The article of manufacture of claim 150, wherein said citric acid is hydrous.
154. The article of manufacture of claim 139, wherein said acid is an organic acid.

T0400T" 88802660

155. The article of manufacture of claim 139, wherein said acid is a mineral acid.

156. The article of manufacture of claim 154, wherein said acid is acetic acid.

157. The article of manufacture of claim 154, wherein said acid is citric acid.

158. The article of manufacture of claim 157, wherein said citric acid is anhydrous.

159. The article of manufacture of claim 157, wherein said citric acid is monohydrous.

160. The article of manufacture of claim 157, wherein said citric acid is hydrous.

161. A method for formulating a pharmaceutical paclitaxel composition such that the paclitaxel does not readily degrade, comprising the steps of:

mixing an acid with a carrier material to form a first carrier composition; and

mixing paclitaxel with said first carrier composition to form a pharmaceutical paclitaxel composition, such that said pharmaceutical paclitaxel composition retains at least 96.6% of the original paclitaxel potency when said pharmaceutical paclitaxel composition is stored at 40°C for seven days.

162. The method of claim 161, wherein said first carrier composition comprises polyethoxylated castor oil.

163. The method of claim 162, wherein said first carrier composition further comprises ethanol.

164. The method of claim 161, wherein said acid is an organic acid.

165. The method of claim 161, wherein said acid is a mineral acid.
166. The method of claim 164, wherein said acid is acetic acid.
167. The method of claim 164, wherein said acid is citric acid.
168. The method of claim 167, wherein said citric acid is anhydrous.
169. The method of claim 167, wherein said citric acid is monohydrous.
170. The method of claim 167, wherein said citric acid is hydrous.
171. The method of claim 162, wherein said acid is an organic acid.
172. The method of claim 162, wherein said acid is a mineral acid.
173. The method of claim 171, wherein said acid is acetic acid.
174. The method of claim 171, wherein said acid is citric acid.
175. The method of claim 174, wherein said citric acid is anhydrous.
176. The method of claim 174, wherein said citric acid is monohydrous.
177. The method of claim 174, wherein said citric acid is hydrous.
178. The method of claim 163, wherein said acid is an organic acid.

101001-23302660

179. The method of claim 163, wherein said acid is a mineral acid.

180. The method of claim 178, wherein said acid is acetic acid.

181. The method of claim 178, wherein said acid is citric acid.

182. The method of claim 181, wherein said citric acid is anhydrous.

183. The method of claim 181, wherein said citric acid is monohydrous.

184. The method of claim 181, wherein said citric acid is hydrous.

185. A method for formulating a pharmaceutical paclitaxel composition such that the paclitaxel does not readily degrade, comprising the steps of:

mixing an acid with a carrier material to form a first carrier composition; and

mixing paclitaxel with said first carrier composition to form a pharmaceutical paclitaxel composition, such that said pharmaceutical paclitaxel composition comprises no more than 2.3% total impurities when stored at 40°C for seven days.

186. The method of claim 185, wherein said first carrier composition comprises polyethoxylated castor oil.

187. The method of claim 186, wherein said first carrier composition further comprises ethanol.

188. The method of claim 185, wherein said acid is an organic acid.

189. The method of claim 185, wherein said acid is a mineral acid.

204. The method of claim 202 wherein said acid is acetic acid.

205. The method of claim 202, wherein said acid is citric acid.

206. The method of claim 205, wherein said citric acid is anhydrous.

207. The method of claim 205, wherein said citric acid is monohydrous.

208. The method of claim 205, wherein said citric acid is hydrous.

209. An article of manufacture produced by the process of:

- (a) obtaining a sealable container;
- (b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that at least 96.6% of the paclitaxel potency is retained when the formulation is stored at 40°C for seven days;
- (c) placing said pharmaceutical formulation in said sealable container;
- (d) sealing said sealable container; and
- (e) storing said pharmaceutical formulation in said sealed container for at least seven days; wherein said pharmaceutical formulation retains at least 96.6% of the original paclitaxel potency.

210. The article of manufacture of claim 209, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.

211. The article of manufacture of claim 210, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

212. The article of manufacture of claim 209, wherein said acid is an organic acid.

213. The article of manufacture of claim 209, wherein said acid is a mineral acid.
214. The article of manufacture of claim 212, wherein said acid is acetic acid.
215. The article of manufacture of claim 212, wherein said acid is citric acid.
216. The article of manufacture of claim 215, wherein said citric acid is anhydrous.
217. The article of manufacture of claim 215, wherein said citric acid is monohydrous.
218. The article of manufacture of claim 215, wherein said citric acid is hydrous.
219. The article of manufacture of claim 210, wherein said acid is an organic acid.
220. The article of manufacture of claim 210, wherein said acid is a mineral acid.
221. The article of manufacture of claim 219, wherein said acid is acetic acid.
222. The article of manufacture of claim 219, wherein said acid is citric acid.
223. The article of manufacture of claim 222, wherein said citric acid is anhydrous.
224. The article of manufacture of claim 222, wherein said citric acid is monohydrous.
225. The article of manufacture of claim 222, wherein said citric acid is hydrous.
226. The article of manufacture of claim 211, wherein said acid is an organic acid.

227. The article of manufacture of claim 211, wherein said acid is a mineral acid.
228. The article of manufacture of claim 226, wherein said acid is acetic acid.
229. The article of manufacture of claim 226, wherein said acid is citric acid.
230. The article of manufacture of claim 229, wherein said citric acid is anhydrous.
231. The article of manufacture of claim 229, wherein said citric acid is monohydrous.
232. The article of manufacture of claim 229, wherein said citric acid is hydrous.
233. An article of manufacture produced by the process of:
- (a) obtaining a sealable container;
 - (b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that the formulation comprises no more than 2.3% total impurities when the formulation is stored at 40°C for seven days;
 - (c) placing said pharmaceutical formulation in said sealable container;
 - (d) sealing said sealable container; and
 - (e) storing said pharmaceutical formulation in said sealed container for at least seven days; wherein said formulation comprises not more than 2.3% total impurities.
234. The article of manufacture of claim 233, wherein said pharmaceutically-acceptable carrier comprises polyethoxylated castor oil.
235. The article of manufacture of claim 234, wherein said pharmaceutically-acceptable carrier further comprises ethanol.

236. The article of manufacture of claim 233, wherein said acid is an organic acid.
237. The article of manufacture of claim 233, wherein said acid is a mineral acid.
238. The article of manufacture of claim 236, wherein said acid is acetic acid.
239. The article of manufacture of claim 236, wherein said acid is citric acid.
240. The article of manufacture of claim 239, wherein said citric acid is anhydrous.
241. The article of manufacture of claim 239, wherein said citric acid is monohydrous.
242. The article of manufacture of claim 239, wherein said citric acid is hydrous.
243. The article of manufacture of claim 234, wherein said acid is an organic acid.
244. The article of manufacture of claim 234, wherein said acid is a mineral acid.
245. The article of manufacture of claim 243, wherein said acid is acetic acid.
246. The article of manufacture of claim 243, wherein said acid is citric acid.
247. The article of manufacture of claim 246, wherein said citric acid is anhydrous.
248. The article of manufacture of claim 246, wherein said citric acid is monohydrous.
249. The article of manufacture of claim 246, wherein said citric acid is hydrous.

0990550100101

250. The article of manufacture of claim 235, wherein said acid is an organic acid.

251. The article of manufacture of claim 235, wherein said acid is a mineral acid.

252. The article of manufacture of claim 250, wherein said acid is acetic acid.

253. The article of manufacture of claim 250, wherein said acid is citric acid.

254. The article of manufacture of claim 253, wherein said citric acid is anhydrous.

255. The article of manufacture of claim 253, wherein said citric acid is monohydrous.

256. The article of manufacture of claim 253, wherein said citric acid is hydrous.

257. A method of making an article of manufacture comprising a sealed container and a pharmaceutical paclitaxel formulation contained therein, said method comprising the steps of:

- (a) obtaining a sealable container;
- (b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that at least 96.6% of the paclitaxel potency is retained when the formulation is stored at 40°C for seven days;
- (c) placing said pharmaceutical formulation in said sealable container;
- (d) sealing said sealable container; and
- (e) storing said pharmaceutical formulation in said sealed container for at least seven days.

258. The method of claim 257, wherein said first carrier composition comprises polyethoxylated castor oil.

259. The method of claim 258, wherein said first carrier composition further comprises ethanol.

260. The method of claim 257, wherein said acid is an organic acid.

261. The method of claim 257, wherein said acid is a mineral acid.

262. The method of claim 260, wherein said acid is acetic acid.

263. The method of claim 260, wherein said acid is citric acid.

264. The method of claim 263, wherein said citric acid is anhydrous.

265. The method of claim 263, wherein said citric acid is monohydrous.

266. The method of claim 263, wherein said citric acid is hydrous.

267. The method of claim 258, wherein said acid is an organic acid.

268. The method of claim 258, wherein said acid is a mineral acid.

269. The method of claim 267 wherein said acid is acetic acid.

270. The method of claim 267, wherein said acid is citric acid.

271. The method of claim 270, wherein said citric acid is anhydrous.

272. The method of claim 270, wherein said citric acid is monohydrous.

273. The method of claim 270, wherein said citric acid is hydrous.

274. The method of claim 259, wherein said acid is an organic acid.

275. The method of claim 259, wherein said acid is a mineral acid.

276. The method of claim 274 wherein said acid is acetic acid.

277. The method of claim 274, wherein said acid is citric acid.

278. The method of claim 277, wherein said citric acid is anhydrous.

279. The method of claim 277, wherein said citric acid is monohydrous.

280. The method of claim 277, wherein said citric acid is hydrous.

281. A method of making an article of manufacture comprising a sealed container and a pharmaceutical paclitaxel formulation contained therein, said method comprising the steps of:

- (a) obtaining a sealable container;
- (b) obtaining a pharmaceutical formulation comprising paclitaxel, a pharmaceutically-acceptable carrier, and an acid; said formulation being such that the formulation comprises no more than 2.3% total impurities when the formulation is stored at 40°C for seven days;
- (c) placing said pharmaceutical formulation in said sealable container;
- (d) sealing said sealable container; and
- (e) storing said pharmaceutical formulation in said sealed container for at least seven days.

282. The method of claim 281, wherein said first carrier composition comprises polyethoxylated castor oil.

283. The method of claim 282, wherein said first carrier composition further comprises ethanol.

284. The method of claim 281, wherein said acid is an organic acid.

285. The method of claim 281, wherein said acid is a mineral acid.

286. The method of claim 284, wherein said acid is acetic acid.

287. The method of claim 284, wherein said acid is citric acid.

288. The method of claim 287, wherein said citric acid is anhydrous.

289. The method of claim 287, wherein said citric acid is monohydrous.

290. The method of claim 287, wherein said citric acid is hydrous.

291. The method of claim 282, wherein said acid is an organic acid.

292. The method of claim 282, wherein said acid is a mineral acid.

293. The method of claim 291, wherein said acid is acetic acid.

294. The method of claim 291, wherein said acid is citric acid.

2025 RELEASE UNDER E.O. 14176

295. The method of claim 294, wherein said citric acid is anhydrous.
296. The method of claim 294, wherein said citric acid is monohydrous.
297. The method of claim 294, wherein said citric acid is hydrous.
298. The method of claim 283, wherein said acid is an organic acid.
299. The method of claim 283, wherein said acid is a mineral acid.
300. The method of claim 298, wherein said acid is acetic acid.
301. The method of claim 298, wherein said acid is citric acid.
302. The method of claim 301, wherein said citric acid is anhydrous.
303. The method of claim 301, wherein said citric acid is monohydrous.
304. The method of claim 301, wherein said citric acid is hydrous.

Ad
a 7